The Food and Drug Administration on Monday approved the anti-psychotic drug Abilify MyCite, the agency's first sign-off of a pill containing electronic tracking sensors. Abilify MyCite uses an electronic signal to record whether or not a patient has ingested the drug; when the pill comes into contact with stomach acid, it generates the signal, which can send data to medical professionals via Bluetooth and a smartphone app. Patients must first sign a consent form before their data can be shared, and they must also wear a patch on their left rib cage that would transmit the information. A 2013 study estimated that people not taking their pills properly costs the U.S. between $100 billion and $289 billion a year and leads to 125,000 deaths annually.

Scroll for 5 things you
need to know now